{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-23-000008","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.771538+00:00","generated_at":"2026-06-19T06:22:37.706431+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PTC Therapeutics reports 2022 revenue of $699M (+30% YoY); reaffirms 2023 guidance of $940M-$1B","bullets":["2022 total revenue $698.8M (+30% YoY); DMD franchise $507M (+20% YoY).","Translarna net revenue $288.6M; Emflaza $218.3M; Evrysdi royalty $113.5M.","Net loss $559M for 2022; cash $410.7M at Dec 31, 2022.","2023 guidance: total revenue $940M-$1B; DMD franchise $545M-$565M.","Four key study readouts expected H1 2023: sepiapterin PKU (May), vatiquinone MIT-E and MOVE-FA, PTC518 HD (Q2)."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-23-000008","json":"https://secwatch.observer/filing/0001070081-23-000008.json","markdown":"https://secwatch.observer/filing/0001070081-23-000008.md","text":"https://secwatch.observer/filing/0001070081-23-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000008/0001070081-23-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000008/tmb-20230221x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:22:37.706431+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d02fcc0687f629588a4d41fdc35c56e3b8c6b3a","claim":"PTC THERAPEUTICS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $167.4 million. Guidance reaffirmed.","evidence_excerpt":"Total revenues were $167.4 million for the fourth quarter of 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000008/0001070081-23-000008-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$167.4 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8b655c98ded23d8f20a902e47cb2b7e52068ec50","claim":"PTC THERAPEUTICS, INC. reported the fiscal year ended December 31, 2022 results: revenue $698.8 million. Guidance reaffirmed.","evidence_excerpt":"Total revenues were $698.8 million for the full year 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000008/0001070081-23-000008-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$698.8 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}